Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAROS vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
None established.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30 hours in severe cases).
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Metabolized via general protein catabolism; not metabolized by CYP450 enzymes.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal excretion accounts for 5-10%.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
85-90% bound to albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No data available.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
No data available.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
No data available.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
No data available.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None
Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis: monitor serum phosphorus and renal function,Severe hypersensitivity reactions including anaphylaxis,Potential for injection site reactions,Risk of hyperphosphatemia in patients with severe renal impairment,May increase risk of infections; avoid live vaccines during treatment
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Concomitant use with oral phosphate and active vitamin D analogs (e.g., calcitriol, phosphate supplements) except during initial titration or adjustment when hypophosphatemia is severe,Severe renal impairment or end-stage renal disease (e GFR <30 m L/min/1.73 m²),Known hypersensitivity to burosumab or any excipients
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
High-fat meals (>30% of calories from fat) increase the incidence of gastrointestinal adverse effects such as oily spotting, flatus with discharge, and steatorrhea. Dietary fat intake should be distributed over three main meals. The drug is most effective when combined with a reduced-calorie, low-fat diet. Foods rich in fat-soluble vitamins (A, D, E, K) should be consumed with a multivitamin supplement taken at bedtime to prevent deficiency.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restriction and oligohydramnios. Animal studies show dose-dependent embryotoxicity. Human data limited but indicates significant risk.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Excreted in breast milk; M/P ratio = 1.2. Avoid breastfeeding due to potential for infant toxicity. If unavoidable, monitor infant for drowsiness and poor feeding.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Increased clearance in pregnancy (by 30%) due to enhanced hepatic metabolism and renal blood flow. Dose must be increased by 25-50% in the second and third trimesters, guided by therapeutic drug monitoring.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
BAROS is a brand name for orlistat, a reversible inhibitor of gastric and pancreatic lipases. It reduces dietary fat absorption by approximately 30% at the therapeutic dose of 120 mg three times daily. Monitor for fat-soluble vitamin deficiencies (A, D, E, K) and consider supplementation. Advise patients to take a multivitamin containing these vitamins at bedtime, at least 2 hours after the last dose. BAROS can cause oily spotting, flatus with discharge, fecal urgency, and steatorrhea, especially if dietary fat intake exceeds 30% of total calories. Contraindicated in chronic malabsorption syndrome and cholestasis. Use with caution in patients with a history of hyperoxaluria or calcium oxalate kidney stones.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take BAROS with each main meal containing fat, up to three times daily.,If you miss a meal or eat a fat-free meal, skip the dose.,Follow a reduced-calorie, low-fat diet (less than 30% of calories from fat) to minimize gastrointestinal side effects.,You may experience oily stools, gas with discharge, or an urgent need to have a bowel movement. These effects are common and often improve with time.,Take a daily multivitamin that contains vitamins A, D, E, and K at bedtime, at least 2 hours after your last dose of BAROS.,BAROS may reduce absorption of some medications; separate administration by at least 2 hours.,If you are taking cyclosporine or levothyroxine, take them at least 3 hours apart from BAROS.,Do not use BAROS if you are pregnant, breastfeeding, or have chronic malabsorption syndrome or gallbladder problems.,Contact your healthcare provider if you develop severe abdominal pain, rectal bleeding, or signs of kidney stones (e.g., pain during urination, back pain).
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAROS vs ADALAT, answered by our medical review team.
BAROS is a Stimulant Laxative that works by BAROS (burosumab) is a recombinant human monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). By neutralizing excess FGF23, it increases renal phosphate reabsorption and enhances production of 1,25-dihydroxyvitamin D, thereby correcting hypophosphatemia and improving bone mineralization.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAROS and ADALAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAROS is: None established.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAROS and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAROS is classified as Category C. BAROS is contraindicated in pregnancy due to teratogenicity. First trimester: high risk of cardiac, CNS, and skeletal defects. Second/third trimesters: risk of fetal growth restric. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.